Why Ki-67? Although it is an important biomarker in oncology (mostly in breast and prostate), Ki-67 immunohistochemistry (IHC) analysis has yet to be ...
Dear customers, shareholders, and our team, As we stand at the threshold of a new year, I wanted to take a moment to review the events of 2023 and express my gratitude for your continued support and hard work that the team has done. It has been a year of important milestones for Aiforia as the first deployments of our clinical AI-solutions were kicked-off in key markets.